Bide Pharmatech Co

Bide Pharmatech Co Financial Leverage

The Financial Leverage (Equity Multiplier) of Bide Pharmatech Co (688073.SS) as of Nov 4, 2026 is 1.23. In the previous year, Financial Leverage (Equity Multiplier) was 1.19 — a change of 3.15% (higher).

Financial Leverage

1.23

YoY

3.15%

Last updated:

Financial Leverage (Equity Multiplier) of Bide Pharmatech Co is 2025 1.23 . Financial Leverage (Equity Multiplier) of Bide Pharmatech Co was 2024 1.19 . It decreases by 3.15% higher compared to the previous year.

The Bide Pharmatech Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2020
1.46 CNY
Jan 1, 2021
1.44 CNY
Jan 1, 2022
1.14 CNY
Jan 1, 2023
1.16 CNY
Jan 1, 2024
1.19 CNY
Jan 1, 2025
1.23 CNY
The Bide Pharmatech Co Financial Leverage history
YEARFinancial LeverageYoY
1.23+3.15%
1.19+3.21%
1.16+1.71%
1.14-21.14%
1.44-1.32%
1.46—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co., Ltd. generates revenue through the research, development, design, production, and sales of pharmaceutical molecular building blocks and scientific reagents. The company's primary products serve drug target discovery, seed compound screening, lead compound discovery, synthesis, and optimization processes. Key markets include Asia Pacific, India, Europe, and the United States, where the firm's offerings are utilized by pharmaceutical companies and research institutions. The business model relies on direct sales of its specialized chemical products to these industry segments. The firm's main focus is on developing molecular building blocks for drug development, with products specifically designed for early-stage pharmaceutical research. These building blocks are essential for creating and refining potential drug candidates. The company's operations span multiple global regions, targeting pharmaceutical manufacturers and academic research organizations that require high-quality chemical compounds for their development pipelines. Bide Pharmatech's revenue streams are derived from the sale of its proprietary molecular building blocks and reagents, which are integral to pharmaceutical R&D processes. The company serves clients in the pharmaceutical sector across Asia Pacific, India, Europe, and the United States, delivering products that support critical stages of drug discovery and development. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bide Pharmatech Co stock

Financial Leverage (Equity Multiplier) of Bide Pharmatech Co is 1.23 in 2025.

Financial Leverage (Equity Multiplier) of Bide Pharmatech Co changed from 1.19 to 1.23, representing a 3.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Bide Pharmatech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co